CSF1R inhibitionitors have been developed as a potential route to reduce the presence of TAMs in the tumor microenvironment. As of 2017, CSF1R inhibitionitors that are currently in early stage clinical trials include Pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, Emactuzumab, AMG820, IMC-CS4, MCS110, and Cabiralizumab.